Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 8, 2019, Pages 1541-1550

  Sandborn, William J ^a   Panés, Julián ^b   D'Haens, Geert R ^c   Sands, Bruce E ^d   Su, Chinyu ^e   Moscariello, Michele ^e   Jones, Thomas ^e   Pedersen, Ron ^e   Friedman, Gary S ^e   Lawendy, Nervin ^e   Chan, Gary ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

Author keywords

Janus Kinase; Malignancies; NMSC; Secondary Analysis

Indexed keywords

PLACEBO; TOFACITINIB; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NON MELANOMA SKIN CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; CLINICAL TRIAL; COLONOSCOPY; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; COLITIS, ULCERATIVE; COLONOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 3; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85061258402     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.11.035     Document Type: Article

References (17)

1. Sandborn, W.J., Su, C., Sands, B.E., et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376 (2017), 1723–1736.
2. Pfizer Inc. XELJANZ prescribing information [Internet]. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=959. (Accessed 30 May 2018)
3. Wollenhaupt, J., Silverfield, J., Lee, E.B., et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41 (2014), 837–852.
4. Cohen, S.B., Tanaka, Y., Mariette, X., et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76 (2017), 1253–1262.
5. Pfizer Inc. FDA Advisory Committee Meeting sNDA 203214 Briefing Document [Internet]. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM599514.pdf. (Accessed 2 July 2018)
6. Sandborn, W.J., Ghosh, S., Panes, J., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367 (2012), 616–624.
7. Winthrop, K.L., Melmed, G.Y., Vermeire, S., et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 24 (2018), 2258–2265.
8. Winthrop, K.L., Curtis, J.R., Lindsey, S., et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 69 (2017), 1960–1968.
9. Winthrop, K.L., Wouters, A., Choy, E.H., et al. The effectiveness of zoster vaccine in RA patients subsequently treated up to 19 months with tofacitinib [abstract]. Arthritis Rheumatol, 68(Suppl 10), 2016, 2609.
10. Kotlyar, D.S., Lewis, J.D., Beaugerie, L., et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13 (2015), 847–858.
11. Peyrin-Biroulet, L., Khosrotehrani, K., Carrat, F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141 (2011), 1621–1628.
12. Charles-Schoeman, C., Wicker, P., Gonzalez-Gay, M.A., et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 46 (2016), 261–271.
13. Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
14. Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265.
15. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
16. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
17. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.